We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Aurora Cannabis Inc. (ACB - Free Report) closed the most recent trading day at $5.93, moving +1.54% from the previous trading session. This change outpaced the S&P 500's 0.79% loss on the day. At the same time, the Dow lost 0.66%, and the tech-heavy Nasdaq lost 0.68%.
Coming into today, shares of the company had lost 13.22% in the past month. In that same time, the Medical sector lost 0.41%, while the S&P 500 lost 1.62%.
Investors will be hoping for strength from ACB as it approaches its next earnings release. In that report, analysts expect ACB to post earnings of -$0.02 per share. This would mark a year-over-year decline of 115.38%. Meanwhile, our latest consensus estimate is calling for revenue of $79.02 million, up 432.49% from the prior-year quarter.
Any recent changes to analyst estimates for ACB should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 2.7% higher within the past month. ACB is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
Aurora Cannabis Inc. (ACB - Free Report) closed the most recent trading day at $5.93, moving +1.54% from the previous trading session. This change outpaced the S&P 500's 0.79% loss on the day. At the same time, the Dow lost 0.66%, and the tech-heavy Nasdaq lost 0.68%.
Coming into today, shares of the company had lost 13.22% in the past month. In that same time, the Medical sector lost 0.41%, while the S&P 500 lost 1.62%.
Investors will be hoping for strength from ACB as it approaches its next earnings release. In that report, analysts expect ACB to post earnings of -$0.02 per share. This would mark a year-over-year decline of 115.38%. Meanwhile, our latest consensus estimate is calling for revenue of $79.02 million, up 432.49% from the prior-year quarter.
Any recent changes to analyst estimates for ACB should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 2.7% higher within the past month. ACB is currently sporting a Zacks Rank of #4 (Sell).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 69, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.